Kashima Jumpei, Okuma Yusuke
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo 104-0045, Japan.
Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.
Semin Cancer Biol. 2022 Nov;86(Pt 2):386-395. doi: 10.1016/j.semcancer.2022.05.005. Epub 2022 May 13.
Treatment for small cell lung cancer (SCLC) has not changed significantly compared to the overwhelming development of targeted therapies for non-small cell lung cancer. However, recent epigenetic and expressional analyses have revealed that SCLC can be divided into four distinct subtypes, which may lead to precision treatments. The situation appears slightly similar to the "four-color problem," a classic mathematical problem stating that no more than four colors are required to color the regions so that no two adjacent areas have the same color. This review introduces the framework for subtyping SCLC into four molecular subtypes and the promising targeted treatment for each subtype.
与非小细胞肺癌靶向治疗的迅猛发展相比，小细胞肺癌（SCLC）的治疗方法并没有显著变化。然而，最近的表观遗传学和表达分析表明，SCLC可分为四种不同的亚型，这可能会带来精准治疗。这种情况似乎与“四色问题”略有相似，“四色问题”是一个经典的数学问题，即对区域进行着色时，只需要不超过四种颜色，就能使相邻的两个区域颜色不同。本文综述了将SCLC分为四种分子亚型的框架以及针对每种亚型的有前景的靶向治疗方法。
